Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Erlotinib in Oral Squamous Cell Carcinoma
NCT02748707Phase 2Unknown
- Sponsor
- Tata Memorial Hospital
- Start
- Aug 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib oral solution and erlotinib in oral squamous cell carcinoma (OSCC) (4 arms), sponsored by Tata Memorial Hospital. Primary endpoint: Change in expression of selected biomarkers in tissue samples at 21 days. Status: unknown.
02
Drugs
celecoxib oral solutionerlotinib
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT02748707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748707.